Catalyst Pharmaceutical Partners (CPRX)

[DonShimoda]

while retail investors are probably focused on CPP109's potential in addiction treatment, as far as take-out speculation goes, the epilepsy drug, CPP115, is what will more likely attract buyout interest. Ovation Pharma's Sabril (vigabatrin) had just received approval, when Lundbeck acquired them for $600mm+ two years ago. Sabril is now generating ~ $100mm in revenue despite a rather dire black box warning label:

Black Box Warning Label: VISION LOSS
Sabril causes progressive and permanent bilateral concentric visual field constriction in a
high percentage of patients. In some cases, Sabril may also reduce visual acuity.
Risk increases with total dose and duration of use, but no exposure to Sabril is known that
is free of risk of vision loss.
Risk of new and worsening vision loss continues as long as Sabril is used, and possibly
after discontinuing Sabril.
Periodic vision testing is required for patients on Sabril, but cannot reliably prevent vision
damage.
Because of the risk of permanent vision loss, Sabril is available only through a special
restricted distribution program.

btw, pre-clinical, CPP115 has shown greater efficacy and a far better safety profile at lower doses. I'm highly anticipating the P1 data due Q1/2 next year. If the data proves out, I would think at the very least Lundbeck would want to protect its investment in Sabril.